MX380557B - Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm). - Google Patents
Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm).Info
- Publication number
- MX380557B MX380557B MX2017014396A MX2017014396A MX380557B MX 380557 B MX380557 B MX 380557B MX 2017014396 A MX2017014396 A MX 2017014396A MX 2017014396 A MX2017014396 A MX 2017014396A MX 380557 B MX380557 B MX 380557B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- multiple myeloma
- specific antibodies
- efficacious
- administered
- Prior art date
Links
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 3
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 2
- 201000000050 myeloid neoplasm Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Display Devices Of Pinball Game Machines (AREA)
Abstract
La presente invención se refiere a un anticuerpo específico para CD38 para usarse en el tratamiento de mieloma múltiple, en donde dicho anticuerpo comprende una cadena pesada variable de la secuencia SEQ ID No: 8 y una cadena ligera variable de la secuencia SEQ ID NO: 9 y una región Fc de IgGI, en donde dicho anticuerpo está adaptado para ser administrable a una dosis de 16 mg/kg o más una vez a la semana (qlw) durante al menos ocho semanas, y en donde dicho anticuerpo está adaptado para ser administrable en combinación con dexametasona.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167597 | 2015-05-13 | ||
| PCT/EP2016/060810 WO2016180958A1 (en) | 2015-05-13 | 2016-05-13 | Treatment for multiple myeloma (mm) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017014396A MX2017014396A (es) | 2018-03-23 |
| MX380557B true MX380557B (es) | 2025-03-12 |
Family
ID=53174925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014396A MX380557B (es) | 2015-05-13 | 2016-05-13 | Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm). |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10533057B2 (es) |
| EP (1) | EP3294769B1 (es) |
| JP (2) | JP7160533B2 (es) |
| KR (1) | KR20180008571A (es) |
| CN (1) | CN107614530A (es) |
| AU (1) | AU2016260895B2 (es) |
| CA (1) | CA2984464C (es) |
| CY (1) | CY1123982T1 (es) |
| DK (1) | DK3294769T3 (es) |
| ES (1) | ES2862708T3 (es) |
| HR (1) | HRP20210552T1 (es) |
| HU (1) | HUE054271T2 (es) |
| IL (1) | IL255552B (es) |
| LT (1) | LT3294769T (es) |
| MX (1) | MX380557B (es) |
| PL (1) | PL3294769T3 (es) |
| PT (1) | PT3294769T (es) |
| RS (1) | RS61668B1 (es) |
| RU (1) | RU2723047C2 (es) |
| SG (1) | SG11201708691VA (es) |
| SI (1) | SI3294769T1 (es) |
| SM (1) | SMT202100202T1 (es) |
| WO (1) | WO2016180958A1 (es) |
| ZA (1) | ZA201708386B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| PL3294769T3 (pl) * | 2015-05-13 | 2021-07-05 | Morphosys Ag | Leczenie szpiczaka mnogiego (mm) |
| CN109689690B (zh) | 2016-07-15 | 2023-10-03 | 武田药品工业株式会社 | 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料 |
| CA3088199A1 (en) | 2018-01-12 | 2019-07-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| AU2019244478B2 (en) * | 2018-03-28 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| AU2019395841B2 (en) * | 2018-12-14 | 2025-02-27 | Morphosys Ag | Antibody formulations |
| EP4588484A3 (en) * | 2019-01-28 | 2025-10-15 | Sanofi-Aventis U.S. LLC | Methods of treating multiple myeloma |
| US20200308296A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| SI2511297T1 (sl) | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
| EP1720907B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
| SG10201912554TA (en) | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CN103554260A (zh) | 2005-10-12 | 2014-02-05 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| EP2641601B8 (en) * | 2006-08-07 | 2016-09-21 | AbbVie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on HuLuc63 with bortezomib |
| PL2081595T3 (pl) * | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2580243B1 (en) * | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| BR112013006769B1 (pt) * | 2010-09-27 | 2021-02-02 | Morphosys Ag | combinação sinérgica |
| WO2014089279A1 (en) * | 2012-12-05 | 2014-06-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds |
| CN103421115B (zh) * | 2013-09-02 | 2015-06-03 | 东南大学 | 一种cd38纳米抗体及应用 |
| JP6600651B2 (ja) | 2014-06-16 | 2019-10-30 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 骨髄腫の治療 |
| MA39070A1 (fr) * | 2014-07-31 | 2017-11-30 | Sanofi Sa | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains |
| US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| EA035979B1 (ru) | 2014-09-09 | 2020-09-08 | Янссен Байотек, Инк. | Варианты комбинированной терапии анти-cd38 антителами |
| PL3294769T3 (pl) * | 2015-05-13 | 2021-07-05 | Morphosys Ag | Leczenie szpiczaka mnogiego (mm) |
-
2016
- 2016-05-13 PL PL16723349T patent/PL3294769T3/pl unknown
- 2016-05-13 LT LTEP16723349.3T patent/LT3294769T/lt unknown
- 2016-05-13 RS RS20210419A patent/RS61668B1/sr unknown
- 2016-05-13 HU HUE16723349A patent/HUE054271T2/hu unknown
- 2016-05-13 CA CA2984464A patent/CA2984464C/en active Active
- 2016-05-13 EP EP16723349.3A patent/EP3294769B1/en active Active
- 2016-05-13 SG SG11201708691VA patent/SG11201708691VA/en unknown
- 2016-05-13 SI SI201631139T patent/SI3294769T1/sl unknown
- 2016-05-13 ES ES16723349T patent/ES2862708T3/es active Active
- 2016-05-13 AU AU2016260895A patent/AU2016260895B2/en active Active
- 2016-05-13 WO PCT/EP2016/060810 patent/WO2016180958A1/en not_active Ceased
- 2016-05-13 KR KR1020177035726A patent/KR20180008571A/ko not_active Ceased
- 2016-05-13 PT PT167233493T patent/PT3294769T/pt unknown
- 2016-05-13 DK DK16723349.3T patent/DK3294769T3/da active
- 2016-05-13 CN CN201680027238.0A patent/CN107614530A/zh active Pending
- 2016-05-13 SM SM20210202T patent/SMT202100202T1/it unknown
- 2016-05-13 RU RU2017137496A patent/RU2723047C2/ru active
- 2016-05-13 HR HRP20210552TT patent/HRP20210552T1/hr unknown
- 2016-05-13 JP JP2017558542A patent/JP7160533B2/ja active Active
- 2016-05-13 MX MX2017014396A patent/MX380557B/es unknown
- 2016-05-13 US US15/569,495 patent/US10533057B2/en active Active
-
2017
- 2017-11-09 IL IL255552A patent/IL255552B/en unknown
- 2017-12-11 ZA ZA2017/08386A patent/ZA201708386B/en unknown
-
2019
- 2019-11-25 US US16/693,904 patent/US11591406B2/en active Active
-
2021
- 2021-03-30 CY CY20211100276T patent/CY1123982T1/el unknown
- 2021-05-06 JP JP2021078658A patent/JP2021130668A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX380557B (es) | Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm). | |
| EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
| BR112015021115A2 (pt) | agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes | |
| EA201891083A1 (ru) | Составы антител к cd38 для подкожного введения и их применение | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| MX373301B (es) | Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos. | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| MX2017010400A (es) | Formulacion liquida estable para anticuerpos monoclonales. | |
| EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
| EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
| CL2016000241A1 (es) | Formulación de inhibidores de la syk. | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| MA52216B1 (fr) | Mirikizumab pour le traitement de la colite ulcéreuse | |
| CL2016001753A1 (es) | Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
| MX2020012826A (es) | Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k). |